VivoSeq
Other

Shoulder Impingement Syndrome

8

Pipeline Programs

1

Active Trials

4

Companies Involved

Shoulder Impingement Syndrome is an early-stage landscape with 8 programs across 4 companies. The most active players are ZARS Pharma Inc., Roche, Milestone Pharmaceuticals Inc.. 3 therapies are approved.

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

40/100

Completion Rate

83/100

Attrition Rate

13/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Trial Status

8

clinical trials

Completed5 · 63%
Unknown status1 · 13%
Withdrawn1 · 13%
Recruiting1 · 13%

Trial Activity

8 trials

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)